紫杉醇顺铂联合治疗晚期非小细胞肺癌32例观察  

Chemotherapy with Paclitaxel Plus Cisplatin in 32 Patients with Advanced Non-small Cell Lung Cancer

作　　者：林运政[1] 庞世权[1] 卜桂兰[1] 吴江[1] 朱海军[1] 潘洁森[1] 

机构地区：[1]深圳市宝安区人民医院肿瘤放疗科,518101

出　　处：《实用癌症杂志》2007年第3期281-283,共3页The Practical Journal of Cancer

摘　　要：目的探讨紫杉醇+顺铂(TP)方案治疗非小细胞肺癌(NSCLC)的近期疗效和毒副反应。方法紫杉醇135mg/m2,d1静滴3h,顺铂14～20mg/m2,d1～d5,静滴,每4周重复。结果入组34例,可评价疗效(化疗2个周期以上)32例,PR12例,NC14例,PD6例,总有效率为37.5%。中位生存期8.5个月,1年生存率18.8%。毒副反应:白细胞降低发生率为81.3%,Ⅲ度降低为18.8%,无Ⅳ度毒副反应;周围神经毒发生率为21.9%,脱发发生率为96.9%,Ⅲ度脱发为12.5%,无Ⅳ度毒副反应。胃肠道反应34.4%。结论TP方案治疗晚期非小细胞肺癌疗效较好,毒副反应可以耐受,生活质量保持稳定。Objective To evaluate the results of combined chemotherapy with paclitaxel （PTX） plus cisplatin（DDP） in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods The chemotherapy regimen consisted of PTX 135 mg/ m^2 by intravenous infusion for 3 hours on day 1, DDP 14 - 20 mg/m^2 by intravenous infusion on day 1 to day 5. The treatment was repeated every 4 weeks. Results A total of 34 patients were entered into the study, and efficacy was evaluable in 32 patients. Of the 32 patients,there were 12 patients with PR, 14 patients with NC and 6 patients with PD, So the overall response rate was 37.5%. The median survival time was 8.5 months and the 1-year survival rate was 18.8%. Adverse effects included leucopenia in 81.3% patients （grade Ⅲ, 18.8% ）, neurotoxicity in 21.9% patients,alopecia in 96.9% patients （grade Ⅲ, 12.5% ）, nansea/vomiting in 34.4% patients. Conclusion The paclitaxel plus cisplatin is a highly effective regimen for patients with advanced NSCLC ,with a manageable toxicities and a stable quality of life.

关 键 词：非小细胞肺癌紫杉醇 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]